Financials

Discussions Technicals Seasonals

6847 fundamentals

Overview Statements Statistics Dividends Earnings Revenue

Key facts

‪1.43 B‬TWD

—

—

−3.22TWD

2016

—

Yan Wen Chen

About

Puriblood Medical Co., Ltd. engages in the developing of technology for blood cell separation that is supported by a research center R&D center for membrane technology RDCMT. PuriBlood is committed to improving the blood filtration process with innovative technology of ‘Zwitterionic bias Surface Coating Technology ZISC technology The company was founded by Dr. Yung Chang in 2016 and is headquartered in Hsinchu, Taiwan.

Valuation

Fundamental metrics to determine fair value of the stock

Summary

‪‪1.43 B‬‬

Price to earning ratio (P/E)

—

Price to sales ratio (P/S)

11.21x

Market Cap

Net income

Revenue

Price to earning ratio (P/E)

—

Price to sales ratio (P/S)

11.21x

Valuation ratios

‪0.00‬

‪7.00‬

‪14.00‬

‪21.00‬

‪28.00‬

H1 '22

H2 '22

H1 '23

H2 '23

H1 '24

‪0.00‬

‪30.00‬

‪60.00‬

‪90.00‬

‪120.00‬

P/E

P/S

Growth and Profitability

Company’s recent performance and margins

Performance

‪−60%‬

‪−30%‬

‪0%‬

‪30%‬

‪60%‬

H1 '22

H2 '22

H1 '23

H2 '23

H1 '24

‪‪−35.00 M‬‬

‪0.00‬

‪‪35.00 M‬‬

‪‪70.00 M‬‬

‪‪105.00 M‬‬

Revenue

Net income

Net margin %

Revenue to profit conversion

Revenue

COGS

Gross profit

Op expenses

Op income

Non-Op income/ expenses

Taxes & Other

Net income

‪‪−15.00 M‬‬

‪0.00‬

‪‪15.00 M‬‬

‪‪30.00 M‬‬

‪‪45.00 M‬‬

Revenue

COGS

Gross profit

Expenses & adjustments

Net income

‪‪−13.00 M‬‬

‪0.00‬

‪‪13.00 M‬‬

‪‪26.00 M‬‬

‪‪39.00 M‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business

Period: 2023

High-end Blood Purification Related Medical Devices and Animal Transfusion

Royalties

Entrusted Technology Development

Other

By country

Period: 2023

Taiwan

Other

Dividends

Dividend yield, history and sustainability

6847 does not pay dividends

The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company

Debt level and coverage

H1 '22

H2 '22

H1 '23

H2 '23

H1 '24

‪‪−50.00 M‬‬

‪0.00‬

‪‪50.00 M‬‬

‪‪100.00 M‬‬

‪‪150.00 M‬‬

Debt

Free cash flow

Cash & equivalents

Financial position analysis

Short term

Long term

‪0.00‬

‪‪35.00 M‬‬

‪‪70.00 M‬‬

‪‪105.00 M‬‬

‪‪140.00 M‬‬

Assets

Liabilities